Novo Integrated Sciences (Novo Integrated Sciences) Operating Income : $-9.38 Mil (TTM As of Feb. 2024)

View and export this data going back to 2005. Start your Free Trial

What is Novo Integrated Sciences Operating Income?

Novo Integrated Sciences's Operating Income for the three months ended in Feb. 2024 was $-1.54 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Feb. 2024 was $-9.38 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. Novo Integrated Sciences's Operating Income for the three months ended in Feb. 2024 was $-1.54 Mil. Novo Integrated Sciences's Revenue for the three months ended in Feb. 2024 was $3.17 Mil. Therefore, Novo Integrated Sciences's Operating Margin % for the quarter that ended in Feb. 2024 was -48.57%.

Warning Sign:

Novo Integrated Sciences Inc operating margin has been in a 5-year decline. The average rate of decline per year is -51.6%.

Novo Integrated Sciences's 5-Year average Growth Rate for Operating Margin % was -51.60% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Novo Integrated Sciences's annualized ROC % for the quarter that ended in Feb. 2024 was -17.09%. Novo Integrated Sciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Feb. 2024 was -83.24%.

Novo Integrated Sciences Operating Income Historical Data

The historical data trend for Novo Integrated Sciences's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novo Integrated Sciences Operating Income Chart

Novo Integrated Sciences Annual Data

Trend

Dec14

Dec15

Dec16

Aug17

Aug18

Aug19

Aug20

Aug21

Aug22

Aug23

Operating Income

Get a 7-Day Free Trial

-0.54

-4.23

-4.27

-9.59

-8.55

Novo Integrated Sciences Quarterly Data
	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24
Operating Income	Get a 7-Day Free Trial															-1.79	-1.43	-3.09	-3.32	-1.54

Novo Integrated Sciences Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Feb. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-9.38 Mil.

Novo Integrated Sciences (NAS:NVOS) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Novo Integrated Sciences's annualized ROC % for the quarter that ended in Feb. 2024 is calculated as:

	ROC % (Q: Feb. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Nov. 2023 )	+	Invested Capital (Q: Feb. 2024 ))	/ count )
=	-6.16 * ( 1 - 0% )	/	( (36.201	+	35.909)	/ 2 )
=	-6.16	/	36.055
=	-17.09 %

where

	Invested Capital		(Q: Nov. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	37.244	-	5.15	-	( 1.64	-	max(0, 10.916	-	6.809	+	1.64	))
=	36.201

	Invested Capital		(Q: Feb. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	34.949	-	3.98	-	( 0.652	-	max(0, 9.959	-	5.019	+	0.652	))
=	35.909

Note: The Operating Income data used here is four times the quarterly (Feb. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Novo Integrated Sciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Feb. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Feb. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Nov. 2023		Q: Feb. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-5.968	/	( ( (7.177 + max(-1.978, 0))	+	(7.163 + max(-1.173, 0)) )	/	2 )
=	-5.968	/	( ( 7.177	+	7.163 )	/	2 )
=	-5.968	/	7.17
=	-83.24 %

where Working Capital is:

	Working Capital		(Q: Nov. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(3.413	+	1.271	+	1.262)	-	(5.15	+	0.035	+	2.739)
=	-1.978

	Working Capital		(Q: Feb. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(2.935	+	0.947	+	1.266)	-	(3.98	+	0	+	2.341)
=	-1.173

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Feb. 2024) EBIT data.

3. Operating Income is also linked to Operating Margin %:

Novo Integrated Sciences's Operating Margin % for the quarter that ended in Feb. 2024 is calculated as:

Operating Margin %	=	Operating Income (Q: Feb. 2024 )	/	Revenue (Q: Feb. 2024 )
	=	-1.54	/	3.171
	=	-48.57 %

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.

Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.

Novo Integrated Sciences Operating Income Related Terms

Thank you for viewing the detailed overview of Novo Integrated Sciences's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Novo Integrated Sciences (Novo Integrated Sciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Novo Integrated Sciences Inc (NAS:NVOS) » Definitions » Operating Income

Comparable Companies

Traded in Other Exchanges

N/A

Address

11120 NE 2nd Street, Suite 100, Bellevue, WA, USA, 98004

Website

https://www.novointegrated.com

Novo Integrated Sciences Inc is a medical care company. It provides specialized physiotherapy, chiropractic care, occupational therapy, eldercare, laser therapeutics, massage therapy, acupuncture, neurological functions, kinesiology, and others. It has two reportable segments: healthcare services which generates majority of the revenue, and product sales.

Executives

Sarfaraz Ali	director	C/O NOVO INTEGRATED SCIENCES, INC.,, 11120 NE 2ND STREET, SUITE 100, BELLEVUE WA 98004
Robert Letterio Oliva	director	115 BELFIELD RD, TORONTO A6 L0J 1C0
Sterling M. Jimenez	officer: Principal Financial Officer	C/O NOVO INTEGRATED SCIENCES, INC.,, 11120 NE 2ND STREET, SUITE 100, BELLEVUE WA 98004
Michael Ross Pope	director	1045 PROGRESS CIRCLE, LAWRENCEVILLE, GEORGIA GA 30043
Alex Flesias	director	41 LANDMARK COURT, UNIONVILLE A6 L3R 9N7
Michael Joseph Gaynor	director	49 BALMORAL ST, KEMPTVILLE A6 K0G 1J0
Robert Mattacchione	director, 10 percent owner, officer: Chief Executive Officer	79 SELVAPIANO CRES, WOODBRIDGE A6 L4H 0X1
Pierre Joseph Dalcourt	director, 10 percent owner	35 BRYANT ST , BOX 2230, HEARST A6 P0L 1N0
Christopher Mehlin David	director, officer: President	10425 SE 22ND ST., BELLEVUE WA 98004
Thomas Edward Bray	officer: Principal Financial Officer	C/O NOVO INTEGRATED SCIENCES, INC., 11120 NE 2ND STREET, SUITE 100, BELLEVUE WA 98004
Rebecca Aw Mcdonald	officer: Chief Accounting Officer	1301 INTERNATIONAL SPEEDWAY BLVD., DELAND FL 32724
James Jr Teters	director	1200 FLIGHTLINE BLVD, STE 5, DELAN FL 32724
Phyllis Rouse	officer: secretary	1200 FLIGHLINE BLVD,, SUITE 5, DELAND FL 32724
Jay Hilden	officer: President & CEO	1200 FLIGHLINE BLVD,, SUITE 5, DELAND FL 32724
Robert Adamo	director	1200 FLIGHTLINE BOULEVARD, SUITE 5, DELAND FL 32724